The therapeutic approach includes first targeting the receptors of vascular endothelial growth factor (VEGFR) with immunotherapy (bevacizumab) or administration of protein kinase inhibitors (sunitinib) approved for advanced stages of cancer [46]. The gene discussed is WEE1; the disease is cancer.